At a glance
A thymosin-related research label with important sequence differences.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Repair and cell-migration findings should be checked against the exact sequence studied. Evidence from topical, animal or veterinary settings does not validate a systemic human regimen.[5][1][5]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of TB-500.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 10 mg · 1 source tables
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
| Phase | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 500 mcg | 15 units (0.15 mL) |
| Weeks 3–4 | 600 mcg | 18 units (0.18 mL) |
| Weeks 5–8 | 750 mcg | 23 units (0.23 mL) |
| Weeks 9–12 | 1000 mcg | 30 units (0.30 mL) |
Frequency: Inject once daily subcutaneously. This schedule uses the largest practical dilution (3.0 mL) to keep per‑injection units in a comfortable range for accurate measurement. Total weekly dose averages ~5 mg, consistent with research protocols[3][4].
Additional schedule context & duration
Concise summary of the once‑daily regimen.
- Goal: Support tissue repair, wound healing, and angiogenesis through the active thymosin beta‑4 fragment mechanism[5][1].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if research goals require).
- Dose Range: 500–1000 mcg daily with gradual titration (~5 mg/week average).
- Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid freeze–thaw cycles of reconstituted solution.
Suggested daily titration approach.
- Start: 500 mcg daily; increase by ~100–150 mcg every 2 weeks as tolerated.
- Target: 750–1000 mcg daily by Weeks 5–12.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–12 weeks; optional extension to 16 weeks based on research protocol.
- Timing: Any consistent time daily; rotate injection sites systematically.
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label with date and concentration; refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality and activity.
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure[6].
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); do not freeze reconstituted solution as freezing can denature peptides.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
- Use reconstituted vials within 28 days when stored with bacteriostatic water preservative[7].
Injection Technique
General subcutaneous guidance from clinical best‑practice resources[12][13].
- Clean the vial stopper and skin with alcohol; allow to air dry completely.
- Pinch a skinfold at the injection site; insert the needle at 45–90° into subcutaneous tissue[12].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[12].
- Rotate sites systematically within approved areas (abdomen, thighs, upper arms) to avoid lipohypertrophy[8].
- Wait 5–10 seconds after injection before withdrawing needle to prevent medication leakage.
Materials & quantity planning
Source materials checklist · 10 mg
Plan based on an 8–16 week daily protocol with gradual titration.
-
Peptide Vials (TB‑500, 10 mg each):
- 8 weeks ≈ 4 vials
- 12 weeks ≈ 7 vials
- 16 weeks ≈ 10 vials
-
Insulin Syringes (U‑100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (4 vials): 12 mL → 2 × 10 mL bottles
- 12 weeks (7 vials): 21 mL → 3 × 10 mL bottles
- 16 weeks (10 vials): 30 mL → 3 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 10 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 01
Research publication
FASEB Journal — Biological activities of thymosin β4 defined by active peptide sequences (TB‑500 fragment identification) (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 02
Research publication
Journal of Chromatography A (PubMed) — Doping control analysis of TB‑500 as synthetic thymosin β4 fragment in biological samples (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 05
Research publication
Journal of Investigative Dermatology (PubMed) — Thymosin beta4 accelerates wound healing (preclinical wound healing model) (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 07
Source document
Empower Pharmacy — Bacteriostatic water injection guidelines (0.9% benzyl alcohol, multi‑dose vial stability) (opens in a new tab)www.empowerpharmacy.com
Back to overview ↑ - 08
Public health resource
NCBI Bookshelf — Best practices for subcutaneous injection (aseptic technique, site rotation) (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 09
- 10
Research publication
Journal of Chromatography B (PubMed) — Quantification of TB‑500 metabolites and wound healing activity screening (prodrug hypothesis) (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 13
Continue exploring
Related topics are not interchangeable compounds or formulations.